trending Market Intelligence /marketintelligence/en/news-insights/trending/JnhZ-3z-H_VBkMHi3kiZAg2 content esgSubNav
In This List

Alnylam Pharmaceuticals prices common stock offering


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

Alnylam Pharmaceuticals prices common stock offering

Alnylam Pharmaceuticals Inc. priced an underwritten public offering of 5 million common shares at $77.50 each.

The Cambridge, Mass.-based biopharmaceutical company expects to raise gross proceeds of about $387.5 million.

Underwriters have a 30-day overallotment option to buy up to 750,000 additional common shares.

Alnylam Pharmaceuticals plans to use the net proceeds for general corporate purposes, including commercialization of Onpattro in the U.S. and Europe. Onpattro, also known as patisiran, is a treatment for the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The rare, genetic, progressive disease is characterized by the formation of the protein called amyloid in the peripheral nerves, heart or gastrointestinal tract.

The offering is expected to close on or about Jan. 17, subject to customary closing conditions.

Barclays Capital Inc. is acting as sole book-running manager for the offering.